34 completed, 16 unknown, 11 recruiting, 8 terminated. 74 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 74 | Completed 34, Unknown 16, Recruiting 11, Terminated 8, Not yet recruiting 3, Withdrawn 2 |
Follow Urologic Neoplasms: new trials by email Literature Review of Urologic Neoplasms trials Research Report on Urologic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Treatment Delivery Preference In People With Kidney Cancer Nivolumab Injectable Product, Nivolumab, Pembrolizumab injection - Renal Cell Carcinoma, Kidney Cancer | Phase 4 | Recruiting | Memorial Sloan Kettering Cancer Center | 40 | 2026-09-24 | 2026-10-16 |
| Innovative and Cooperative Pathway Integrating Oncogeriatric, Pharmaceutical and Pharmacological Follow-up in Elderly Patients. Experimental - Elderly, Breast Cancer | Phase 4 | Not yet recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 794 | 2026-09-01 | 2026-09-03 |
| Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study Biospecimen Collection, Immune Checkpoint Inhibitor - Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma | Phase 4 | Recruiting | OHSU Knight Cancer Institute | 160 | 2026-04-24 | 2026-10-13 |
| Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer Accelerometry, BCG Solution, Electronic Health Record Review - Non-Muscle Invasive Bladder Carcinoma | Phase 4 | Recruiting | Ohio State University Comprehensive Cancer Center | 40 | 2026-02-26 | 2026-03-16 |
| Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs) PDD-TURBT with hexaminolevulinate (Hexvix®), Power Led Saphira (TM) - Non-muscle-invasive Bladder Cancer, Non-Muscle Invasive Bladder Urothelial Carcinoma | Phase 4 | Recruiting | University of Roma La Sapienza | 327 | 2025-12-22 | 2025-12-31 |
| Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma cabozantinib and nivolumab - Renal Cell Carcinoma (Kidney Cancer), Metastatic Renal Cell Carcinoma | Phase 4 | Recruiting | Centre Francois Baclesse | 83 | 2025-10-01 | 2026-07-14 |
| Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations. Deferred Cytoreductive Nephrectomy + medical treatment, Radiotherapy + medical treatment, Medical therapy - Renal Cell Cancer, Kidney Neoplasm | Phase 4 | Recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 409 | 2025-06-15 | 2025-07-03 |
| Chemoablation Or Bladder Resection With Adjuvant Chemotherapy in Recurrent Non-Muscle Invasive Bladder Cancer Mitomycin c - Non-Muscle Invasive Bladder Cancer | Phase 4 | Recruiting | Jakob Kristian Jakobsen | 272 | 2025-06-01 | 2025-10-03 |
| Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma Nivolumab, Cabozantinib - Kidney Cancer, Renal Cell Cancer | Phase 4 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 50 | 2025-05-16 | 2025-09-24 |
| Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial Biospecimen Collection, Computed Tomography, Cystectomy - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma | Phase 4 | Recruiting | Mayo Clinic | 75 | 2025-01-08 | 2026-10-01 |
| The Impact of PDD During TURB for NMIBC Transurethral resection of the bladder performed with PDD tecnique and Hexvix - Bladder Cancer | Phase 4 | Not yet recruiting | A.O.U. Città della Salute e della Scienza | 300 | 2024-09-01 | 2024-08-12 |
| A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose. nadofaragene firadenovec - Bladder Cancer, Ta/T1 | Phase 4 | Withdrawn | Ferring Pharmaceuticals | 2024-06-17 | 2024-11-22 | |
| OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults Olaparib, Lenvatinib, Sunitinib - Renal Cell Carcinoma, Ovarian Carcinoma | Phase 4 | Unknown | University Medical Center Groningen | 30 | 2024-05-01 | 2023-11-29 |
| Fluid Challenge and Plasma Volume, During Surgery acetated Ringers, albumin 5%, albumin 20% - Colorectal Cancer, Urologic Cancer | Phase 4 | Completed | Joachim Zdolsek | 65 | 2023-10-23 | 2026-11-10 |
| Preop Laxatives in Robotic Urologic Surgery Polyethylene Glycol 3350 - Prostate Cancer, Kidney Cancer | Phase 4 | Recruiting | Chad R. Tracy | 240 | 2023-06-01 | 2025-05-30 |
| The Nephroprotective Effect of Metformin With Cisplatin in Bladder Cancer Metformin Hydrochloride 500 MG - Muscle-Invasive Bladder Carcinoma | Phase 4 | Unknown | Cairo University | 78 | 2023-06-01 | 2024-08-20 |
| Effect of Intravesical B.C.G and Gemcitabine on Semen Analysis and Testicular Volume in NMIBC Bacillus Calmette Guerin, Gemcitabine HCL (Gemzar) - Urothelial Carcinoma Bladder, Sperm Count, Low | Phase 4 | Completed | Assiut University | 86 | 2023-04-01 | 2026-10-29 |
| Safety and Efficacy of BCG Combined With Tislelizumab for BCG-untreated Patients With High-risk Non-muscle Invasive Bladder Cancer BCG combined with Tislelizumab - Non-muscle-invasive Bladder Cancer | Phase 4 | Unknown | Ruijin Hospital | 42 | 2022-10-09 | 2022-10-14 |
| A Clinical Study of Disitamab Vedotin for Injection Combined With Penpulimab Injection in Neoadjuvant Therapy for Patients With HER2-expressing Cisplatin-intolerant cT2-T4aNxM0 Bladder Urothelial Carcinoma Disitamab Vedotin for Injection,Penpulimab Injection - Bladder Cancer | Phase 4 | Unknown | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 48 | 2022-09-01 | 2022-08-04 |
| Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients low-dose neuroleptanalgesia, Placebo - Stomach Neoplasms, Colonic Neoplasms | Phase 4 | Unknown | RenJi Hospital | 200 | 2021-10-05 | 2021-10-06 |
Showing 20 of 74. Sign in to see all of them.
Urinary Bladder Neoplasms (27) · Carcinoma, Renal Cell (26) · Kidney Neoplasms (21) · Non-Muscle Invasive Bladder Neoplasms (9) · Carcinoma, Non-Small-Cell Lung (5) · Lung Neoplasms (5) · Liver Neoplasms (4) · Neoplasms (4) · Prostatic Neoplasms (4) · Carcinoma, Hepatocellular (3) · Neoplasm Metastasis (3) · Recurrence (3) · Stomach Neoplasms (3) · Breast Neoplasms (2)
Female Urogenital Diseases (74) · Female Urogenital Diseases and Pregnancy Complications (74) · Male Urogenital Diseases (74) · Neoplasms by Site (74) · Urogenital Diseases (74) · Urogenital Neoplasms (74) · Urologic Diseases (74) · Neoplasms (70) · Kidney Diseases (40) · Neoplasms by Histologic Type (38) · Neoplasms, Glandular and Epithelial (36) · Carcinoma (35) · Urinary Bladder Diseases (35) · Adenocarcinoma (26)
Nivolumab (7) · Everolimus (5) · Sunitinib (5) · 5-aminolevulinic acid hexyl ester (3) · BCG Vaccine (3) · Mitomycin (3) · pazopanib (3) · Anesthesia, Epidural (2) · Doxorubicin (2) · Epirubicin (2) · Fentanyl (2) · Gemcitabine (2) · Ipilimumab (2) · Midazolam (2) · Neostigmine (2)
Bristol-Myers Squibb (4) · Mansoura University (4) · Novartis Pharmaceuticals (4) · Medical University of Warsaw (3) · Assiut University (2) · Gustave Roussy, Cancer Campus, Grand Paris (2) · M.D. Anderson Cancer Center (2) · iOMEDICO AG (2) · A.O.U. Città della Salute e della Scienza (1) · Ankara Training and Research Hospital (1) · Ankara University (1) · Asan Medical Center (1) · Assistance Publique - Hôpitaux de Paris (1) · Azienda Ospedaliera "Sant'Andrea" (1) · Bayer (1)
United States (19) · Egypt (7) · France (6) · China (5) · Germany (4) · Turkey (Türkiye) (4) · Denmark (3) · India (3) · Italy (3) · Poland (3) · Russia (3) · Sweden (3) · Netherlands (2) · South Korea (2) · Algeria (1)
Ahmed Mosbah, MD (3) · Ahmed Elhussein, MBBCH (2) · Ahmed Elkarta, MBBCH (2) · Karolina Dobronska, MD (2) · Abdelwahab R. Hashem, Msc (1) · Ahmed Harraz, MD (1) · Ahmed M Eltaher, professor (1) · Ahmed Moeen (1) · Andrea Tubaro (1) · Anne Sophie P. Kancir, MD PhD (1) · Atallah A. Shaaban, MD (1)
PMID 21266057, PMID 21319349, PMID 21655015, PMID 21775497, PMID 22241828, PMID 22704310, PMID 23170127, PMID 23733379, PMID 23759377, PMID 23982601, PMID 25466382, PMID 27101285, PMID 30448030, PMID 31780139, PMID 32738823, PMID 33070307, PMID 33300144, PMID 33537703, PMID 33552568, PMID 34611902, PMID 34791718, PMID 35210307, PMID 36104138, PMID 36223555, PMID 37230961, PMID 38842053, PMID 39397266, PMID 39868569, PMID 40279497, PMID 40319155, PMID 40375148, PMID 41801644, PMID 42433301
2015 (1), 2017 (1), 2025 (1), R01CA091912 (1)